Literature DB >> 22521106

Mitochondrial pharmacology.

Robin A J Smith1, Richard C Hartley, Helena M Cochemé, Michael P Murphy.   

Abstract

Mitochondria are being recognized as key factors in many unexpected areas of biomedical science. In addition to their well-known roles in oxidative phosphorylation and metabolism, it is now clear that mitochondria are also central to cell death, neoplasia, cell differentiation, the innate immune system, oxygen and hypoxia sensing, and calcium metabolism. Disruption to these processes contributes to a range of human pathologies, making mitochondria a potentially important, but currently seemingly neglected, therapeutic target. Mitochondrial dysfunction is often associated with oxidative damage, calcium dyshomeostasis, defective ATP synthesis, or induction of the permeability transition pore. Consequently, therapies designed to prevent these types of damage are beneficial and can be used to treat many diverse and apparently unrelated indications. Here we outline the biological properties that make mitochondria important determinants of health and disease, and describe the pharmacological strategies being developed to address mitochondrial dysfunction.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521106     DOI: 10.1016/j.tips.2012.03.010

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  150 in total

Review 1.  Reactive Oxygen Species: the Dual Role in Physiological and Pathological Conditions of the Human Body.

Authors:  Sanaa K Bardaweel; Mustafa Gul; Muhammad Alzweiri; Aman Ishaqat; Husam A ALSalamat; Rasha M Bashatwah
Journal:  Eurasian J Med       Date:  2018-10

Review 2.  The Aging Heart.

Authors:  Ying Ann Chiao; Peter S Rabinovitch
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-01       Impact factor: 6.915

Review 3.  First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

Authors:  Hazel H Szeto
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

4.  Hypoxia/oxidative stress alters the pharmacokinetics of CPU86017-RS through mitochondrial dysfunction and NADPH oxidase activation.

Authors:  Jie Gao; Xuan-sheng Ding; Yu-mao Zhang; De-zai Dai; Mei Liu; Can Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2013-10-14       Impact factor: 6.150

Review 5.  Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Steven J Sollott
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

Review 6.  Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.

Authors:  Nadezda Apostolova; Victor M Victor
Journal:  Antioxid Redox Signal       Date:  2015-03-10       Impact factor: 8.401

Review 7.  Pharmacological modulation of mitochondrial ion channels.

Authors:  Luigi Leanza; Vanessa Checchetto; Lucia Biasutto; Andrea Rossa; Roberto Costa; Magdalena Bachmann; Mario Zoratti; Ildiko Szabo
Journal:  Br J Pharmacol       Date:  2019-01-02       Impact factor: 8.739

Review 8.  Mitochondria and endothelial function.

Authors:  Matthew A Kluge; Jessica L Fetterman; Joseph A Vita
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

9.  Eugenia uniflora leaf essential oil promotes mitochondrial dysfunction in Drosophila melanogaster through the inhibition of oxidative phosphorylation.

Authors:  Nélson R de Carvalho; Nathane R Rodrigues; Giulianna E Macedo; Ivi J Bristot; Aline A Boligon; Marli M de Campos; Francisco A B Cunha; Henrique D Coutinho; Fabio Klamt; Thomas J S Merritt; Thaís Posser; Jeferson L Franco
Journal:  Toxicol Res (Camb)       Date:  2017-05-05       Impact factor: 3.524

10.  1,4-naphthoquinone cations as antiplasmodial agents: hydroxy-, acyloxy-, and alkoxy-substituted analogues.

Authors:  Xiao Lu; Ali Altharawi; Jiri Gut; Philip J Rosenthal; Timothy E Long
Journal:  ACS Med Chem Lett       Date:  2012-10-01       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.